Across the globe, legislation surrounding the application of cannabinoid compounds towards human health is gaining momentum. Corresponding with new regulations is a dramatic increase in cannabinoid-based treatment options—from just a few drugs in the early 2000s to now over 300 medical products currently in human trials for ailments such as post-traumatic stress disorder, nervous system degeneration, depression, epileptic seizures, Parkinson's disease, multiple sclerosis and schizophrenia. Consumption of medicinal cannabis is currently legal in over 40 countries and 33 states in the US, with the global sector estimated by some industry analysts to be worth over USD 62.6 billion by 2024 [1]. Legalization of medicinal cannabis is under consideration in over a dozen other countries, and more jurisdictions can be expected to follow suit if the evidence for efficacy of medicinal cannabis increases.

中文翻译：

---

I&M 的未来趋势：用于药用大麻生产的下一代测量技术

在全球范围内，围绕大麻素化合物对人类健康的应用的立法正在获得动力。与新法规相对应的是，基于大麻素的治疗选择急剧增加——从 2000 年代初期的几种药物到现在超过 300 种正在人体试验中的医疗产品，例如创伤后应激障碍、神经系统退化、抑郁症、癫痫发作、帕金森病、多发性硬化症和精神分裂症。医用大麻的消费目前在美国 40 多个国家和 33 个州是合法的，一些行业分析师估计，到 2024 年，全球部门的价值将超过 626 亿美元 [1]。其他十几个国家正在考虑将药用大麻合法化，